Decheng Capital
Overview
Decheng Capital is a venture capital firm that provides capital and strategic support to early-stage life science companies and growth-stage healthcare companies.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Baylor Genetics | Jul 2026 | Series B | Lead |
| Remix Therapeutics | Jun 2026 | Private Placement | Lead |
| Serapha Bio | Jun 2026 | Series A | Co-investor |
| Cellares | Jun 2026 | Series D | Co-investor |
| Vivacta Biotechnology (Shanghai) Co., Ltd. | Apr 2026 | Series A | Lead |
For institutional investors. Book with your work email.
Key People
Dan Zabrowski
Venture Partner
Dayton Misfeldt
Partner
Nick Pliam
Partner
Qiang Xu
Partner
Michael Notaras
Vice President - Biotech Public Equities Venture Capital
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Decheng Capital based?
Decheng Capital is headquartered in Menlo Park, California, United States.
When was Decheng Capital founded?
Decheng Capital was founded in 2012.
How many portfolio companies does Decheng Capital have?
Decheng Capital has 54 portfolio companies in Caplight's dataset.
What are some companies in Decheng Capital's portfolio?
Recent investments visible on Caplight include Baylor Genetics, Remix Therapeutics, Serapha Bio, Cellares, Vivacta Biotechnology (Shanghai) Co., Ltd..
What was Decheng Capital's most recent investment?
Decheng Capital's most recent investment on Caplight was in Baylor Genetics in 2026.
What sectors does Decheng Capital focus on?
Decheng Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure, AI, Data & Cloud Infrastructure, AI, Data & Cloud Infrastructure, Consumer & Commerce, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech.
What company stages does Decheng Capital focus on?
Stage focus information for Decheng Capital is not publicly available.
What is Decheng Capital's AUM?
Decheng Capital's assets under management are estimated between $2.5B and $3.0B.